公司资料
Incyte 股价、新闻与催化剂
- 股票代码:
- INCY
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Wilmington, Delaware
股票表现
117.14 USD (-3.47%)
收盘价
最后更新: 2026年10月1日
18.4B USD
市值
股价为何变动
截至 2026年10月1日，INCY 下跌 3.47%，收于 $117.14。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Research-Based Biopharmaceutical Company
Incyte discovers, develops, and commercializes medicines across hematology, oncology, and inflammation and autoimmunity. The company has built an internal discovery engine around targeted small molecules and biologics while expanding its commercial footprint through both wholly owned and partnered products.
Hematology Franchise
The hematology business is anchored by Jakafi and Jakafi XR across myelofibrosis, polycythemia vera, and graft-versus-host disease. Monjuvi/Minjuvi and Niktimvo extend the franchise into B-cell lymphoma and chronic graft-versus-host disease, while INCA033989 targets mutant calreticulin in myeloproliferative neoplasms.
Oncology Portfolio
Incyte's oncology portfolio includes Zynyz and Pemazyre as well as clinical candidates targeting KRAS G12D, TGF-beta receptor 2, and CDK2. Development emphasizes biomarker-defined tumors and combinations with established chemotherapy, antibodies, and antiangiogenic agents.
Dermatology and Autoimmune Medicines
Opzelura is a topical JAK inhibitor commercialized for atopic dermatitis and vitiligo, with studies underway in additional inflammatory skin diseases. Povorcitinib, an oral JAK1 inhibitor, is being developed across hidradenitis suppurativa, prurigo nodularis, asthma, and other immune-mediated conditions.
Acquired and Partnered Pipeline
The acquisition of Vega Therapeutics added latarcibart, a once-monthly antibody in Phase 3 development for von Willebrand disease. Incyte also uses collaborations for formulation technology, regional commercialization, and selected pipeline assets, complementing its internally generated programs.
未来催化剂
- Potential U.S. approval and launch of Monjuvi for newly diagnosed diffuse large B-cell lymphoma in the first quarter of 2027.
- Topline Phase 2 data for axatilimab plus ruxolitinib in newly diagnosed chronic graft-versus-host disease in the second half of 2026.
- Presentation of INCB161734 and INCA33890 Phase 1 combination data at ESMO 2026.
- Initiation of a Phase 3 study of INCB123667 in first-line maintenance ovarian cancer in the second half of 2026.
- Phase 3 TRuE-HS1 and TRuE-HS2 topline results for ruxolitinib cream in hidradenitis suppurativa in the fourth quarter of 2026.
- Potential European launch of povorcitinib in late 2026 and potential U.S. approval and launch in the first quarter of 2027.
- Phase 3 STOP-PN1 and STOP-PN2 data for povorcitinib in prurigo nodularis in the fourth quarter of 2026.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。